Ptak Roger G, Gallay Philippe A, Jochmans Dirk, Halestrap Andrew P, Ruegg Urs T, Pallansch Luke A, Bobardt Michael D, de Béthune Marie-Pierre, Neyts Johan, De Clercq Erik, Dumont Jean-Maurice, Scalfaro Pietro, Besseghir Kamel, Wenger Roland M, Rosenwirth Brigitte
Southern Research Institute, Frederick, Maryland 21701, USA.
Antimicrob Agents Chemother. 2008 Apr;52(4):1302-17. doi: 10.1128/AAC.01324-07. Epub 2008 Jan 22.
Debio-025 is a synthetic cyclosporine with no immunosuppressive capacity but a high inhibitory potency against cyclophilin A (CypA)-associated cis-trans prolyl isomerase (PPIase) activity. A lack of immunosuppressive effects compared to that of cyclosporine was demonstrated both in vitro and in vivo. For three cyclosporines, the inhibitory potential against PPIase activity was quantitatively correlated with that against human immunodeficiency virus type 1 (HIV-1) replication. Debio-025 selectively inhibited the replication of HIV-1 in a CD4+ cell line and in peripheral blood mononuclear cells: potent activity was demonstrated against clinical isolates of various HIV-1 subtypes, including isolates with multidrug resistance to reverse transcriptase and protease inhibitors. Simian immunodeficiency virus and HIV-2 strains were generally resistant to inhibition by Debio-025; however, some notable exceptions of sensitive HIV-2 clinical isolates were detected. In two-drug combination studies, additive inhibitory effects were found between Debio-025 and 19 clinically used drugs of different classes. Clinical HIV-1 isolates that are naturally resistant to Debio-025 and that do not depend on CypA for infection were identified. Comparison of the amino acid sequences of the CypA binding domain of the capsid (CA) protein from Debio-025-sensitive and -resistant HIV-1 isolates indicated that resistance was mostly associated with an H87Q/P exchange. Mechanistically, cyclosporines competitively inhibit the binding of CypA to the HIV-1 CA protein, which is an essential interaction required for early steps in HIV-1 replication. By real-time PCR we demonstrated that early reverse transcription is reduced in the presence of Debio-025 and that late reverse transcription is almost completely blocked. Thus, Debio-025 seems to interfere with the function of CypA during the progression/completion of HIV-1 reverse transcription.
Debio-025是一种合成环孢素,无免疫抑制能力,但对亲环蛋白A(CypA)相关的顺反脯氨酰异构酶(PPIase)活性具有高抑制效力。与环孢素相比,其缺乏免疫抑制作用在体外和体内均得到证实。对于三种环孢素,其对PPIase活性的抑制潜力与对1型人类免疫缺陷病毒(HIV-1)复制的抑制潜力呈定量相关。Debio-025在CD4+细胞系和外周血单核细胞中选择性抑制HIV-1复制:对各种HIV-1亚型的临床分离株均显示出强效活性,包括对逆转录酶和蛋白酶抑制剂具有多药耐药性的分离株。猿猴免疫缺陷病毒和HIV-2毒株通常对Debio-025的抑制具有抗性;然而,检测到一些敏感的HIV-2临床分离株的显著例外情况。在两药联合研究中,发现Debio-025与19种不同类别的临床常用药物之间具有相加抑制作用。鉴定出了对Debio-025天然耐药且感染不依赖CypA的临床HIV-1分离株。对Debio-025敏感和耐药的HIV-1分离株衣壳(CA)蛋白的CypA结合域氨基酸序列进行比较表明,耐药性主要与H87Q/P交换有关。从机制上讲,环孢素竞争性抑制CypA与HIV-1 CA蛋白的结合,这是HIV-1复制早期步骤所需的关键相互作用。通过实时PCR我们证明,在存在Debio-025的情况下早期逆转录减少,晚期逆转录几乎完全受阻。因此,Debio-025似乎在HIV-1逆转录的进行/完成过程中干扰CypA的功能。